Global Renal Cell Cancer (RCC) Disease Forecast and Market 2019-2038: Sutent Continues to be the Most Widely Prescribed Therapy in Locally Advanced and Metastatic RCC

News provided by

Jun 19, 2019, 06:30 ET

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Renal cell cancer (RCC) disease forecast and market analysis to 2038" report has been added to ResearchAndMarkets.com's offering.

Renal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms tumor (nephroblastoma).

The incidence of RCC is higher in those over the age of 60 years, suggesting that the aging population may play a significant role in current and future disease burden. Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.

Market Snapshot

The PD-1/PD-L1 class is set to experience significant growth, with annual sales forecast to reach $3.2bn by 2026.
Sutent continues to be the most widely prescribed therapy in locally advanced and metastatic RCC.
Incident cases of RCC are expected to increase by around a quarter during 2018-38.
Numerous therapies will soon experience generic erosion with the expiries of key patents.
PD-1/PD-L1 therapies are set to dominate the first-line treatment of advanced RC
Combination therapies pose challenges for payers.

Key Topics Covered:

Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Afinitor
Product Profile: Avastin
Product Profile (Late Stage): Bavencio
Product Profile (Late Stage): Cb-839
Product Profile: Cabometyx
Product Profile: Fotivda
Product Profile: Inlyta
Product Profile (Late Stage): Keytruda
Product Profile: Lenvima
Product Profile: Nexavar
Product Profile: Opdivo
Product Profile: Sutent
Product Profile (Late Stage): Tecentriq
Product Profile: Torisel
Product Profile: Votrient
Product Profile (Late Stage): Abexinostat

Treatment: Renal Cell Carcinoma (Published On 16 February 2018)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends

Epidemiology: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

Marketed Drugs: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Product Overview
Product Profile: Afinitor
Product Profile: Avastin
Product Profile: Cabometyx
Product Profile: Fotivda
Product Profile: Inlyta
Product Profile: Lenvima
Product Profile: Nexavar
Product Profile: Opdivo
Product Profile: Sutent
Product Profile: Torisel
Product Profile: Votrient

Renal Cell Cancer Pricing, Reimbursement, And Access (Published On 22 August 2018)
Overview
Regulatory Labels
Global Access Levers
Evidence And Value
Access To Recently Approved And Pipeline Drugs
Pricing
US
Canada
Japan
France
Germany
Italy
Spain
UK
Methodology

Pipeline: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Bavencio
Product Profile (Late Stage): Cb-839
Product Profile (Late Stage): Keytruda
Product Profile (Late Stage): Tecentriq
Product Profile (Late Stage): Abexinostat

For more information about this report visit https://www.researchandmarkets.com/r/2og07l

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets